Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burtness

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
Head & Neck|October 12, 2013
p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primaryLanea M Keller, Thomas J Galloway, Thomas Holdbrook, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancerBarbara Burtness, Laurie Thomas, Rebecca Sipples, et al.
Cancer Research Communications|April 14, 2023
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell CarcinomaNiki Gavrielatou, Ioannis Vathiotis, Thazin Nwe Aung, et al.
Head & Neck|April 1, 2025
Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckAarti Bhatia, Ranee Mehra, Jessica Bauman, et al.
American Journal of Clinical Oncology|November 11, 2010
Increased recurrences using intensity-modulated radiation therapy in the postoperative settingAruna Turaka, Tianyu Li, Navesh K Sharma, et al.
Oncotarget|August 13, 2015
Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neckTim N Beck, John Kaczmar, Elizabeth Handorf, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Anticancer Research|September 15, 2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyGokoulakrichenane Loganadane, Benjamin H Kann, Henry S Park, et al.
Oncogene|January 17, 2019
APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinomaVincent L Cannataro, Stephen G Gaffney, Tomoaki Sasaki, et al.
Cancers|July 9, 2020
Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell CarcinomaStefan P Haider, Tal Zeevi, Philipp Baumeister, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
Head & Neck|October 12, 2013
p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primaryLanea M Keller, Thomas J Galloway, Thomas Holdbrook, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancerBarbara Burtness, Laurie Thomas, Rebecca Sipples, et al.
Cancer Research Communications|April 14, 2023
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell CarcinomaNiki Gavrielatou, Ioannis Vathiotis, Thazin Nwe Aung, et al.
Head & Neck|April 1, 2025
Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckAarti Bhatia, Ranee Mehra, Jessica Bauman, et al.
American Journal of Clinical Oncology|November 11, 2010
Increased recurrences using intensity-modulated radiation therapy in the postoperative settingAruna Turaka, Tianyu Li, Navesh K Sharma, et al.
Oncotarget|August 13, 2015
Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neckTim N Beck, John Kaczmar, Elizabeth Handorf, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Anticancer Research|September 15, 2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyGokoulakrichenane Loganadane, Benjamin H Kann, Henry S Park, et al.
Oncogene|January 17, 2019
APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinomaVincent L Cannataro, Stephen G Gaffney, Tomoaki Sasaki, et al.
Cancers|July 9, 2020
Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell CarcinomaStefan P Haider, Tal Zeevi, Philipp Baumeister, et al.
Pageof 19